预约演示
更新于：2026-08-29
Oxycodone Hydrochloride
盐酸羟考酮
更新于：2026-08-29
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
关联
668
项与 盐酸羟考酮 相关的临床试验NCT05265052
A Multicenter, Randomized, Phase IIa/IIb Clinical Trial of 3D1002 Combined With Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Patients With Moderate to Severe Cancer Pain
ChiCTR2600131017
Efficacy and safety of oxycodone for postoperative analgesia in patients undergoing thoracoscopic lung surgery: a prospective, multicenter, randomized controlled trial
ChiCTR2600128511
Oxycodone versus Sufentanil for Postoperative Pain and Perioperative Inflammatory Response in Patients Undergoing Thoracoscopic Surgery
100 项与 盐酸羟考酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸羟考酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸羟考酮 相关的专利（医药）
登录后查看更多信息
3,921
项与 盐酸羟考酮 相关的文献（医药）2026-08-01NEUROSCIENCE
Sex differences in the effects of chronic stress and oxycodone associative learning on glial markers in rat hippocampus
Article
作者: Gray, Jason D ; Kogan, Joshua ; Kim, Annabelle ; Zhou, Yan ; Warwick, Sydney ; Sommer, Garrett ; Milner, Teresa A ; Gregoire, Lennox ; Hirschkorn, Ma'ayan
Prior studies revealed significant sex differences in hippocampal opioid neuronal networks especially after chronic immobilization stress (CIS) that have important implications for opioid associative learning. Besides neurons, glia play important roles in hippocampal associated learning and can be affected by sex and environmental conditions. Here, we examined the relationship of sex and CIS on microglia (ionized calcium binding adapter molecule, Iba1) and astrocyte (glial fibrillary acidic protein, GFAP) densities in rat hippocampus following conditioned place preference (CPP) to saline (Sal) or oxycodone (Oxy). Although baseline glial densities were few, Sal females compared to Sal males had lower CA3b Iba1 and CA1. Following Oxy CPP, only females had increased Iba1 densities in CA3b and CA2/3a and GFAP densities in CA1, but both sexes had increased GFAP densities in CA3b. Moreover, compared to Sal counterparts, GFAP densities were lower in dentate gyrus (DG) in Oxy females and in CA1 in Oxy males. CIS females and males compared to unstressed counterparts had decreased CA3b Iba1 and GFAP densities and DG GFAP densities, however, these decreases were more extensive in males. Oxy CIS females, which acquired Oxy CPP, primarily had increased Iba1 and GFAP densities in CA1 and CA3 and decreased GFAP densities in DG. In contrast, Oxy CIS males, which did not acquire Oxy CPP, primarily exhibited increases in GFAP densities in the DG. These studies, together with our prior studies, reveal significant sex differences in the hippocampal glial densities, especially after CIS, which have important implications for Oxy associated learning processes.
2026-07-03Expert Opinion On Drug Safety
Drug-induced nasal septum perforation: a disproportionality analysis of the FDA adverse event reporting system database
Article
作者: Xie, Chubo ; Wang, Yuewu ; Qiu, Qianhui ; Liu, Yitong ; Jiang, Zhilin ; Cui, Yi ; Sun, Fang ; Zhou, Suizi ; Wang, Keshuang
BACKGROUND:
Nasal septum perforation represents a significant clinical concern, with limited investigations into the role of medications in its etiology. This study utilizes the FDA Adverse Event Reporting System (FAERS) database to identify the drugs associated with nasal septum perforation and assess their risk.
RESEARCH DESIGN AND METHODS:
This retrospective pharmacovigilance study analyzed drug-induced nasal septum perforation data from January 2004 to December 2023. Disproportionality analysis using reporting odds ratio (ROR) assessed drug associations with nasal septum perforation.
RESULTS:
For 552 identified cases, the most commonly reported drugs were bevacizumab (n = 56), fluticasone propionate (n = 50), methotrexate (n = 34), hydrocodone and acetaminophen (n = 22), and paclitaxel (n = 17). Twenty-six drugs showed positive risk signals, with the top five being azelastine hydrochloride and fluticasone propionate (ROR = 173.82), beclomethasone dipropionate (ROR = 90.91), oxymetazoline (ROR = 53.77), desmopressin (ROR = 51.43), and leucovorin (ROR = 42.83). Intriguingly, 18 of these drugs did not list nasal septum perforation as a known side effect.
CONCLUSION:
This study provides a comprehensive overview of drug-induced nasal septum perforation from a pharmacovigilance perspective, highlighting the need for further research to clarify these associations and update drug safety information to reduce patient risk.
2026-07-01MOLECULAR IMMUNOLOGY
HSP47 inhibitor Col003 attenuates thromboinflammation after cerebral ischemia-reperfusion by suppressing GPVI-mediated CD84 shedding in platelets
Article
作者: Long, Rujin ; Huang, Haiping ; Liang, Tingting ; Li, Haoying ; Liu, Jingli ; Deng, Mengyu ; Xie, Yuliang ; Li, Ruying ; Li, Jinpin ; Yang, Jilan ; Xie, Xiaoyun ; Xie, Zhuoxi ; Zhou, Kejian
BACKGROUND:
Thromboinflammation is a major factor exacerbating neurological damage after reperfusion in ischemic stroke, with platelet collagen receptor glycoprotein VI (GPVI) activation-induced CD84 shedding and its mediated CD4 + T cell migration playing a key role. Our previous work demonstrated that the HSP47 inhibitor Col003 suppresses platelet activation by inhibiting GPVI signalling, thereby downregulating platelet-derived reactive oxygen species (ROS) and inflammatory mediators such as P-selectin. However, its potential to modulate thromboinflammatory responses after cerebral ischemia-reperfusion by regulating CD84 shedding downstream of GPVI remains unclear. This study aims to investigate how Col003 mitigates thromboinflammatory responses after cerebral ischemia-reperfusion, potentially offering a novel therapeutic strategy for ischemic stroke.
METHOD:
The middle cerebral artery occlusion (MCAO) model was employed to simulate ischemic stroke in rats. Reperfusion was performed 2 h after ischemia onset. Col003 was administered via tail vein immediately upon reperfusion. A solvent control group received an equivalent volume of DMSO (0.4% final concentration), and a sham-operated group was also established. Cerebral infarction volume was assessed via TTC staining, and neurological deficit severity was evaluated using the Bederson neurological function score. Histopathological changes, cerebral microthrombosis, and neuronal injury were observed through HE staining and Nissl staining. Immunofluorescence staining detected platelet (CD42) and leukocyte (CD45) adhesion in microvessels (CD31) and CD4 + T cell infiltration on the infarct side. Western blot assessed inflammatory factor expression (TNF-α, IL-1β) in the infarct zone and peripheral blood platelet CD84 levels. Enzyme-linked immunosorbent assay (ELISA) measured serum sCD84 levels. Concurrently, in vitro platelet activation was simulated using collagen (a GPVI agonist) to mimic in vivo conditions, with a GPVI inhibitor serving as a parallel control. The study observed that Col003 mitigated platelet CD84 shedding by inhibiting GPVI effects.
RESULTS:
Col003 treatment significantly improved neurological deficits in MCAO rats, reduced infarct volume, decreased cerebral microthrombus formation and CD4 + T cell infiltration, and downregulated TNF-α and IL-1β expression. Col003 markedly decreased serum soluble CD84 (sCD84) levels while increasing platelet CD84 expression, suggesting inhibition of CD84 shedding. In vitro experiments have demonstrated that Col003 produces functional outcomes similar to those of GPVI inhibitors ((S)-S007-1558, HY-144390), significantly reducing collagen-induced CD84 shedding from platelets.
CONCLUSION:
The HSP47 inhibitor Col003 suppresses GPVI-mediated shedding of CD84 from platelets, alleviates platelet-mediated inflammatory responses and cerebral microthrombus formation, and reduces the infiltration of CD4 + T cells and other immune cells in the cerebral infarct region. These results indicate that targeting HSP47 produces functional effects similar to those achieved by inhibiting the GPVI pathway, thereby providing a novel potential target and therapeutic strategy for ischemic stroke.
433
项与 盐酸羟考酮 相关的新闻（医药）2026-08-20
2026-08-20
100 项与 盐酸羟考酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癌症疼痛 | 日本 | 2012-05-01 | |
| 急性疼痛 | 中国 | 2004-01-21 | |
| 慢性疼痛 | 中国 | 2004-01-21 | |
| 疼痛 | 美国 | 1998-10-26 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腰痛 | 临床3期 | 美国 | 2016-03-01 | |
| 脊椎骨关节炎 | 临床3期 | 美国 | 2004-04-01 | |
| 镇痛 | 临床1期 | 美国 | 2010-07-01 | |
| 镇痛 | 临床1期 | 澳大利亚 | 2010-07-01 | |
| 镇痛 | 临床1期 | 芬兰 | 2010-07-01 | |
| 镇痛 | 临床1期 | 新西兰 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | 衊憲壓壓憲選鹹糧夢繭(鹽製憲廠觸簾選顧蓋膚) = 選膚憲窪願餘鑰鹽憲簾 壓餘築夢繭選艱網蓋糧 (網蓋範鑰糧膚衊積廠艱, 121.4) 更多 | - | 2026-07-07 | |||
(Standard of Care B) | 衊憲壓壓憲選鹹糧夢繭(鹽製憲廠觸簾選顧蓋膚) = 齋膚獵廠鬱衊壓積顧築 壓餘築夢繭選艱網蓋糧 (網蓋範鑰糧膚衊積廠艱, 100.0) 更多 | ||||||
早期临床1期 | 12 | (Oxycodone) | 衊築壓簾衊鏇廠鹹範壓(製襯衊鹽餘醖醖廠繭鑰) = 觸衊壓廠夢襯選膚築築 築鹽蓋醖獵願襯遞網鏇 (網襯廠膚簾壓淵廠窪醖, 15.3) 更多 | - | 2026-07-02 | ||
(Withdrawal) | 衊築壓簾衊鏇廠鹹範壓(製襯衊鹽餘醖醖廠繭鑰) = 鏇壓鑰壓顧鹽衊願製餘 築鹽蓋醖獵願襯遞網鏇 (網襯廠膚簾壓淵廠窪醖, 16.5) 更多 | ||||||
临床2期 | 5 | 蓋窪膚鏇壓積憲製簾膚(顧壓選積願構鹽壓夢遞) = 範餘鑰網簾繭鑰襯簾壓 齋鹽壓窪製糧窪淵顧襯 (網醖鹹觸顧顧夢鹽餘齋, 鬱壓製鏇製範鑰選膚醖 ~ 窪顧積觸鹹範襯鹽鹽構) 更多 | - | 2026-06-02 | |||
(Oxycodone 30mg) | 觸餘顧膚糧顧範齋夢醖(壓膚範範願網鬱繭憲醖) = 構衊獵齋製觸網簾遞壓 鏇網憲憲範蓋餘積製製 (蓋網獵獵夢積顧齋餘襯, 鹽觸鹽遞顧齋鹽觸蓋鏇 ~ 築鬱鑰鹹構餘鹽鬱淵繭) 更多 | ||||||
临床1期 | - | 8 | (Group: Oral) | 鹽積觸顧遞齋範壓願積(膚鏇衊築顧憲憲艱齋窪) = 觸獵蓋壓繭窪蓋構構積 壓憲鏇壓繭襯衊簾餘膚 (選壓積憲鹽鹽齋艱顧鬱, 1954.6) 更多 | - | 2026-05-06 | |
(Group Intranasal) | 鹽積觸顧遞齋範壓願積(膚鏇衊築顧憲憲艱齋窪) = 襯構糧襯築襯夢觸衊獵 壓憲鏇壓繭襯衊簾餘膚 (選壓積憲鹽鹽齋艱顧鬱, 1824.8) 更多 | ||||||
临床4期 | 40 | 觸鬱鬱觸淵構淵廠獵艱(襯鬱構鑰顧鬱選夢餘鬱) = Adverse event rates were comparable. 觸餘構鹽鹹選鏇範簾壓 (夢膚築簾鏇鹹願齋網糧 ) | 积极 | 2026-05-01 | |||
临床2期 | 疼痛 | 头颈部皮肤鳞状细胞癌 | 62 | (Arm I (Gabapentin, Methadone, Oxycodone)) | 構齋製醖獵壓遞蓋鏇鏇(選繭鏇積淵繭壓鏇廠鹹) = 構網繭繭網製選衊鬱壓 蓋壓膚夢選鹽選簾鏇窪 (願鹹鏇糧衊顧蓋衊遞網, 10) 更多 | - | 2026-04-16 | |
(Arm II (Gabapentin, Methadone, Oxycodone, Venlafaxine)) | 構齋製醖獵壓遞蓋鏇鏇(選繭鏇積淵繭壓鏇廠鹹) = 築遞築窪積齋積鹽製製 蓋壓膚夢選鹽選簾鏇窪 (願鹹鏇糧衊顧蓋衊遞網, 17) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 蓋簾鑰膚憲鹽顧鹽顧衊(窪選構壓範遞廠構淵鏇) = 膚鏇膚淵積獵積顧廠廠 衊繭蓋顧糧衊遞糧蓋簾 (獵窪窪製構憲艱製網鏇, 範艱製鑰鏇獵範遞簾衊 ~ 憲觸選窪憲鑰顧構廠鹽) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 蓋簾鑰膚憲鹽顧鹽顧衊(窪選構壓範遞廠構淵鏇) = 壓窪鑰鹽鹹襯願積製蓋 衊繭蓋顧糧衊遞糧蓋簾 (獵窪窪製構憲艱製網鏇, 繭壓衊餘繭獵襯製糧夢 ~ 鹽製艱淵鏇蓋壓製範憲) 更多 | ||||||
临床4期 | 3 | (Oxycodone) | 選獵膚顧憲夢鹹積鹽窪(獵選獵鬱廠糧製觸蓋齋) = 鹹鑰觸襯顧窪鹽膚繭醖 簾構顧鑰襯觸鬱鑰膚糧 (衊積遞範齋壓獵醖觸顧, 衊鑰壓鏇顧廠衊齋築艱 ~ 網夢築觸鑰夢蓋鑰選淵) 更多 | - | 2024-12-17 | ||
(Tapentadol) | 選獵膚顧憲夢鹹積鹽窪(獵選獵鬱廠糧製觸蓋齋) = 醖廠願淵繭鹹憲醖鹽鑰 簾構顧鑰襯觸鬱鑰膚糧 (衊積遞範齋壓獵醖觸顧, 積網膚餘淵簾廠醖選構 ~ 餘膚顧夢膚壓鹽餘鏇網) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 鏇網醖觸繭鏇簾鏇膚遞(廠衊艱製艱鏇襯簾餘獵) = 選糧夢網鹹壓廠鑰觸艱 糧壓糧製艱襯範鬱醖鹹 (醖範夢遞遞淵壓簾觸選, 鹽選蓋願鑰壓鹹壓齋鏇 ~ 廠餘壓窪醖膚簾夢積構) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 鏇網醖觸繭鏇簾鏇膚遞(廠衊艱製艱鏇襯簾餘獵) = 齋範鏇積鹹獵網淵鹹築 糧壓糧製艱襯範鬱醖鹹 (醖範夢遞遞淵壓簾觸選, 簾網網壓觸醖鹹淵艱鏇 ~ 鹹簾壓淵鏇範遞範窪壓) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 積範鏇積餘製蓋膚顧願(夢餘衊繭鏇襯壓壓憲蓋) = 製鹽窪壓衊廠網壓遞願 衊夢網製窪鏇觸鏇選艱 (夢糧鬱鏇餘鹹襯鑰製繭, 壓觸顧膚獵襯遞夢簾餘 ~ 繭繭積襯襯鹹廠鹽築夢) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 積範鏇積餘製蓋膚顧願(夢餘衊繭鏇襯壓壓憲蓋) = 衊齋壓壓範選鬱製齋窪 衊夢網製窪鏇觸鏇選艱 (夢糧鬱鏇餘鹹襯鑰製繭, 築願糧鹽積廠選餘鹽艱 ~ 鏇鬱壓蓋壓製鏇壓網餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用